Effect of an ongoing educational program on the use of antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs in patients with coronary artery disease seen in an academic cardiology clinic.
The effect of an ongoing educational program on the use of cardiovascular drugs in patients with coronary artery disease without contraindications to these drugs seen in an academic cardiology clinic was assessed in 100 patients seen during the 6-month period prior to the educational program and in 200 patients seen 9 to 20 months after the onset of the educational program. Following the educational program, the use of aspirin, clopidogrel, or warfarin increased from 69 to 99%, the use of beta- blockers increased from 57 to 98%, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers increased from 41 to 97%, and the use of lipid-lowering drugs in patients with dyslipidemia increased from 54 to 98% in patients without contraindications to these drugs.
Nayak
Devraj
D
Cardiology Division, Department of Medicine, Westchester Medical Center/New York Medical College, Valhalla, NY 10595, USA.
Aronow
Wilbert S
WS
D000046:Academic Medical Centers; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002309:Cardiology / Q000193:education*; D016507:Cardiology Service, Hospital; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004502:Education, Medical, Continuing; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009518:New York; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015397:Program Evaluation; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors